Accreditation Information

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Endocrine Unit, Massachusetts General Hospital.  Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Needs Statement

This activity seeks to update and educate healthcare providers on topics related to the thyroid gland, where knowledge gaps may exist. Participants will learn about the novel approaches to thyroidectomies and to non-surgical options for thyroid  nodules. In addition, they will be able to better understand indications, contraindications, risks and benefits of novel medical treatment for thyroid eye disease.

Objectives

Upon completion of this activity, participants will be able to:

  • Identify alternative options for the management of thyroid nodules.
  • Describe outcome expectations for novel medical management options for patients with thyroid eye disease.

Target Audience

Specialty physicians, Physician assistants, Nurse practitioners, and Nurses interested in endocrinology and thyroid pathology and surgery.

Faculty Disclosure

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.